Year All News20232022202120202019201820172016 May 10 2023 Achilles Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights Read More + May 10 2023 Achilles Therapeutics’ New Immunogenicity Prediction Application of its AI-Powered PELEUS™ Platform Uniquely Identifies the Most Potent T Cell Antigens Read More + Apr 25 2023 Achilles Therapeutics Announces Grant of US Patent Covering the Treatment of Patients with an Immunotherapy Targeting Neoantigens Based on Tumor HLA Status Read More + Apr 25 2023 Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement Read More + Apr 17 2023 Achilles Therapeutics to Present at Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit Read More + Mar 7 2023 Achilles Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Business Highlights Read More +
May 10 2023 Achilles Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights Read More +
May 10 2023 Achilles Therapeutics’ New Immunogenicity Prediction Application of its AI-Powered PELEUS™ Platform Uniquely Identifies the Most Potent T Cell Antigens Read More +
Apr 25 2023 Achilles Therapeutics Announces Grant of US Patent Covering the Treatment of Patients with an Immunotherapy Targeting Neoantigens Based on Tumor HLA Status Read More +
Apr 25 2023 Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement Read More +
Apr 17 2023 Achilles Therapeutics to Present at Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit Read More +
Mar 7 2023 Achilles Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Business Highlights Read More +
